BACKGROUND: Childhood B-cell lymphomas (B-NHLs) represent a group of aggressive malignancies that are amenable to high-intensity chemotherapy regimens. In 1992, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a prospective clinical trial involving the diagnosis and treatment of childhood B-NHL based on a well established strategy developed by the Berlin-Frankfurt-Munster Group. METHODS: Between November 1992 and October 1997, 163 children who had B-NHL were treated prospectively in the first national AIEOP trial. Disease staging was performed according to the St. Jude staging system, and treatment was assigned on the basis of risk group (R1, R2, or R3), which took into account disease stage and resectability and serum lactate dehydrogenase (LDH) levels. RESULTS: Of the 144 evaluable patients, 11 had Stage I disease, 35 had Stage II disease, 76 had Stage III disease, and 22 had Stage IV disease. Thirteen, 54, and 77 patients were included in risk groups R1, R2, and R3, respectively. The 10-year overall survival (OS) and event-free survival (EFS) rates for the overall population were 89.4% and 81.8%, respectively; the EFS rates for patients in risk groups R1, R2, and R3 were 100%, 86.9%, and 75.1%, respectively. Multivariate analysis indicated that age > or = 10 years, disease histology other than Burkitt or Burkitt-like lymphoma, and LDH levels > or = 1000 international units per liter had negative prognostic value. Analysis of the toxicity (according to the World Health Organization grading system) associated with 710 of the 748 chemotherapy cycles administered revealed 855 cases of Grade 3 or 4 toxicity, with 73% being cases of hematologic toxicity. Toxic episodes were most common after the first chemotherapy cycle and were equally common in the R2 and R3 risk groups. To date, the development of a second malignancy has not been observed in any patient in the study cohort. CONCLUSIONS: Long-term follow-up of the current study (AIEOP LNH92) confirms the observation of a favorable outcome for patients with B-NHL treated with short, intensive chemotherapy regimens and raises the possibility that non-Burkitt or non-Burkitt-like histology and age > or = 10 years may have negative prognostic value for patients with childhood B-NHL. Copyright 2004 American Cancer Society.
BACKGROUND: Childhood B-cell lymphomas (B-NHLs) represent a group of aggressive malignancies that are amenable to high-intensity chemotherapy regimens. In 1992, the Italian Association of Pediatric Hematology and Oncology (AIEOP) initiated a prospective clinical trial involving the diagnosis and treatment of childhood B-NHL based on a well established strategy developed by the Berlin-Frankfurt-Munster Group. METHODS: Between November 1992 and October 1997, 163 children who had B-NHL were treated prospectively in the first national AIEOP trial. Disease staging was performed according to the St. Jude staging system, and treatment was assigned on the basis of risk group (R1, R2, or R3), which took into account disease stage and resectability and serum lactate dehydrogenase (LDH) levels. RESULTS: Of the 144 evaluable patients, 11 had Stage I disease, 35 had Stage II disease, 76 had Stage III disease, and 22 had Stage IV disease. Thirteen, 54, and 77 patients were included in risk groups R1, R2, and R3, respectively. The 10-year overall survival (OS) and event-free survival (EFS) rates for the overall population were 89.4% and 81.8%, respectively; the EFS rates for patients in risk groups R1, R2, and R3 were 100%, 86.9%, and 75.1%, respectively. Multivariate analysis indicated that age > or = 10 years, disease histology other than Burkitt or Burkitt-like lymphoma, and LDH levels > or = 1000 international units per liter had negative prognostic value. Analysis of the toxicity (according to the World Health Organization grading system) associated with 710 of the 748 chemotherapy cycles administered revealed 855 cases of Grade 3 or 4 toxicity, with 73% being cases of hematologic toxicity. Toxic episodes were most common after the first chemotherapy cycle and were equally common in the R2 and R3 risk groups. To date, the development of a second malignancy has not been observed in any patient in the study cohort. CONCLUSIONS: Long-term follow-up of the current study (AIEOP LNH92) confirms the observation of a favorable outcome for patients with B-NHL treated with short, intensive chemotherapy regimens and raises the possibility that non-Burkitt or non-Burkitt-like histology and age > or = 10 years may have negative prognostic value for patients with childhood B-NHL. Copyright 2004 American Cancer Society.
Authors: Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte Journal: J Clin Oncol Date: 2012-01-03 Impact factor: 44.544
Authors: Catherine Patte; Anne Auperin; Mary Gerrard; Jean Michon; Ross Pinkerton; Richard Sposto; Claire Weston; Martine Raphael; Sherrie L Perkins; Keith McCarthy; Mitchell S Cairo Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis Journal: PLoS One Date: 2022-09-30 Impact factor: 3.752
Authors: Birgit Burkhardt; Mary Taj; Nathalie Garnier; Veronique Minard-Colin; Volkan Hazar; Karin Mellgren; Tomoo Osumi; Alina Fedorova; Natalia Myakova; Jaime Verdu-Amoros; Mara Andres; Edita Kabickova; Andishe Attarbaschi; Alan Kwok Shing Chiang; Eva Bubanska; Svetlana Donska; Lisa Lyngsie Hjalgrim; Jacek Wachowiak; Anna Pieczonka; Anne Uyttebroeck; Jelena Lazic; Jan Loeffen; Jochen Buechner; Felix Niggli; Monika Csoka; Gergely Krivan; Julia Palma; G A Amos Burke; Auke Beishuizen; Kristin Koeppen; Stephanie Mueller; Heidi Herbrueggen; Wilhelm Woessmann; Martin Zimmermann; Adriana Balduzzi; Marta Pillon Journal: Cancers (Basel) Date: 2021-04-25 Impact factor: 6.639
Authors: G A Amos Burke; Veronique Minard-Colin; Anne Aupérin; Sarah Alexander; Marta Pillon; Rafael Delgado; József Zsíros; Anne Uyttebroeck; Peggy Dartigues; Rodney R Miles; Bernarda Kazanowska; Alan K Chiang; Stéphanie Haouy; Catherine M Bollard; Monika Csoka; Keith Wheatley; Donald A Barkauskas; Peter C Adamson; Gilles Vassal; Catherine Patte; Thomas G Gross Journal: J Clin Oncol Date: 2021-09-27 Impact factor: 50.717
Authors: Clément Bailly; Thomas Eugène; Marie-Laure Couec; Marion Strullu; Eric Frampas; Loïc Campion; Françoise Kraeber-Bodéré; Caroline Bodet-Milin Journal: Front Med (Lausanne) Date: 2014-12-16